Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding medicaid

American Journal of Public Health

Volumn 91, Issue 9, 2001, Pages 1464-1473

  Kahn, J G ^a   Haile, B ^a   Kates, J ^a   Chang, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; DISEASE MODEL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDICAID; MEDICARE; VIRUS LOAD;

EID: 0034875046     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.91.9.1464     Document Type: Article

References (93)

1. HIV-1 protease inhibitors: A review for clinicians
2. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase,SQV) plus HIVID (salcitabine, ddC)
3. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 Study
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
6. Prevalence of HIV infection in the United States 1984 to 1992
7. Antiretroviral usage patterns before and after instituting national treatment guidelines
8. Insurance and race predict access to HIV protease inhibitors
9. AIDS drugs give little hope to thousands unable to pay
10. Expense means many can't get drugs for AIDS
11. Viral load combination therapy for HIV [letter]
12. Predictors for not currently receiving protease inhibitor therapy: Results from a multisite interview project
13. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States
14. The care of HIV-infected adults in the United States
15. The "Medicaidization" of AIDS: Trends in the financing of HIV-related medical care
16. Caring for people with human immunodeficiency virus infection [editorial]
17. White House drops plan to cover cost of AIDS drugs for poor
18. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
19. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas
20. Scope of the AIDS epidemic in the United States
21. A minimum estimate of the number of living HIV infected persons confidentially tested in the United States [abstract]
22. HIV Outpatient Study Group. Recent patterns of antiretroviral therapy and clinical response in ambulatory HIV patients
23. Plasma viral load CD4+ lymphocytes as prognostic marker of HIV-1 infection
24. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study
25. Slow progression to AIDS in intravenous drug users infected with HIV in Norway
26. The Italian Seroconversion Study. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion
27. Pre-AIDS mortality in the Edinburgh city hospital HIV cohort
28. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users; plasma viral load and CD4+ cell count
29. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: A comparison with male homosexuals
30. Immunologic markers of AIDS progression: Consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I
31. Longer survival after HIV infection for injecting drug users than for homosexual men: Implications for immunology
32. The natural history of HIV infection in intravenous drug users: Risk of disease progression in a cohort of seroconverters
33. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter
34. Immunodeficiency and the risk of death in HIV infection
35. Effect of comprehensive intervention program on survival of patients with human immunodeficiency virus infection
36. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
37. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
38. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
39. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count>50/μL
40. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population
41. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine
42. Changes in AIDS survival time in two San Francisco cohorts of homosexual men 1983 to 1993
43. Survival differences in Austrian patients with the acquired immunodeficiency syndrome
44. Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection
45. Long-term survival in patients with advanced immunodeficiency
46. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
47. Survival in a cohort of 1205 AIDS patients from Milan [letter]
48. Survival after AIDS among Italian haemophiliacs with HIV infection
49. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
50. A population-based comparison of the clinical course of children and adults with AIDS
51. Estimation of time from seroconversion to AIDS in HIV-infected intravenous drug users in the US
52. The progression of untreated HIV-1 infection prior to AIDS
53. Rate of AIDS defining events (ADEs) and resulting cost of care: Indinavir (IDV) in combination with zidovudine (ZDV) [or stavudine (d4T)] + lamivudine (3TC) versus ZDV [or d4T] + 3TC
54. Incidence rates and risk factors for opportunistic infections in a phase trial comparing indinavir + ZDV + 3TC to ZDV + 3TC
55. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
56. Prolongation of life and prevention of AIDS complication in advanced HIV immunodeficiency with ritonavir update
57. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS
58. Decline in CMV and other opportunistic disease with combination antiretroviral therapy
59. Six year improvement in HIV hospital outcomes at Cook County Hospital, Chicago: Impact of AIDS care units and HAART
60. Protease inhibitors are associated with declining AIDS deaths in New York City
61. Influence of antiretroviral combinations on disease progression and survival in HIV infected patients Aquitaine (France), 1988-97
62. Treatment of primary HIV with AZT, 3TC, and indinavir
63. Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQV/HIV protease inhibitor) and Epivir (3TC/lamivudine) and Retrovir (ZDV/zidovudine) in HIV-infected patients
64. Double (3TC+d4T) vs triple (3TC+d4T+saquinavir) therapy in HIV-1 experienced patients (ZDV+ddC/ddl) with a low baseline HIV-1 viral load (median 4.098 copies/ml)
65. Efficacy of zidovudine, lamivudine and ritonavir combination in patients with symptomatic primary HIV-1 infection: The ANRS 053/53B trial. Can eradication be obtained?
66. An open randomized study to test the influence of maintaining a pre-established viral load reduction in the progression of chronic HIV-1 infected patients in very early stages
67. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
68. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
69. The relations of virologic immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
70. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
71. Treatment with indinavir, zidovudine, and lamivudine in adults with HIV and prior antiretroviral therapy
72. The lifetime cost of treating a person with HIV
73. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland
74. Cost of care for patients with human immunodeficiency virus infection; patterns of utilization and charges in a public health care system
75. AIDS treatment costs during the 1st months of life: Evidence from the ACSUS
76. Impact of combination therapy for HIV infection on inpatient census [letter]
77. Inversion of inpatient/outpatient HIV service utilization: Impact of improved therapies, clinician education and case management in the US Department of Veterans Affairs
78. Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of HAART
79. Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 × 10(6)/1
80. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
81. Medicaid's problem children: Eligible but not enrolled
82. Strategies for long-term success in the treatment of HIV infection
83. Cost effectiveness of combination HIV therapy: Three years later
84. Early treatment with highly active antiretroviral therapy (HAART) is cost-effective compared to delayed treatment
85. Combination antiretroviral therapy in HIV infection an economic perspective
86. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]
87. Drug company cuts cost of AIDS treatment